17,261 trials
Herniorrhaphy · Postoperative Pain · Inguinal Hernia
Primary: Sum of Pain Intensity Defined as Area Under the Curve (AUC) of 100-mm VAS PI Scores. — 2810.4; 3484.5 score on a scale*hour
Systemic Lupus Erythematosus
Primary: Mean Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Improvement Compared to Placebo. — -6.2; -6.5; -6.2; -5.7 Scores on a scale — p=0.845
Arterial Occlusive Diseases · Coronary Artery Disease · Coronary Disease
Primary: First Occurrence of Major Plus Minor Thrombolysis in Myocardial Infarction (TIMI) Bleeding Events; Number/Percentage of Observed Participants With Outcome Measure Events…
Pulmonary Hypertension · Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change in 6 Minute Walk Test — 7.00; 16.60; 16.00; 4.90 Meters walked in 6 minutes
Neuroendocrine Tumors
Primary: Objective Response Rate (ORR) — 1 Participants
HIV Infections
Primary: Change in Short-term Virologic Response — -.11; -.15; -.16; -.16 log(10) copies/mL per day
Smoking Cessation · Smoking, Cigarette · Nicotine Dependence
Primary: Craving Levels in Response to Cue — 69.6; 66.3; 56.1; 74.4 score on a scale
Opioid-use Disorder
Primary: Sublocade Induction — 10 Participants
Type 2 Diabetes Mellitus
Primary: Change From Baseline in HbA1c — -0.58; -0.57; -0.66 HbA1C % — p=<0.001
Kaposi's Sarcoma
Primary: Number of Participants With a Decrease in Kaposi's Sarcoma (KS) Total Surface Area — 11 Participants
Nephrotic Syndrome · Focal Segmental Glomerulosclerosis · Minimal Change Disease
Primary: Percentage of Participants in Renal Response at Day 113 — 0.0; 7.7; 12.5; 33.3 Percent of Participants
Prostate Cancer
Primary: Number of Participants With Overall Response as Determined by iRECIST — 1; 1; 3; 9 Participants
Liver Transplant · Liver Transplantation
Primary: The Percent of Participants Who Achieve Operational Tolerance 52 Weeks After Completion of Immunosuppression Withdrawal. — 16.4 Percent of Participants
Progressive Desmoids Tumors
Primary: Percentage of Patients Remaining Alive and Progression-free at 6 Months as Per RECIST 1.1 After the Day of Randomisation (6-month Non-progression Rate). — 84.8; 45.0…
Renal Cell Carcinoma
Primary: Objective Response Rate at Week 24 (ORR24W) — 32.1; 34.8 percentage of participants — p=0.2676